Friday, April 26, 2019
ADCs for Glioblastoma
Glioblastoma is a particularly nasty form of cancer, and has the unfortunate issue of being located behind the blood-brain barrier. This adds a significant complication to treatment, and as such has made it very difficult for treatments to have any more than incremental patient benefit.
Because of this, researchers at Columbia University are doing some really interesting trials where you add in multiple different therapies into a single cohort. In this was a traditional blind study can be extended to more treatments. This saves time, increases the likelihood that the best path forward is discovered, and also increases the likelihood of a patient receiving treatment instead of placebo.
One of these treatments being tested is a glioblastoma treatment from AbbVie called Depatuxizumab Mafodotin. Depatuxizumab Mafodotin (ABT-414) is an antibody drug conjugate (ADC) targeting EGFR-amplification that is being investigated to treat glioblastoma (GBM).
The preliminary results from Phase I trials are encouraging, and as such it is progressing into late phase trials currently. The Phase I results can be viewed here:
And if there isn't enough information for you yet, here is a very interesting discussion with Dr. Manmeet Ahluwalia from the Cleveland Clinic about the currently ongoing UPFRONT clinical trial: